Global Flu Vaccines Market, By Influenza Type (Seasonal, Zoonotic), Manufacturing Technology (Egg-Based, Cell Culture-Based, Recombinant-Based), Vaccine Type (Quadrivalent Influenza Vaccines, Trivalent Influenza Vaccines, Whole Virus Vaccines, Split Virus Vaccines, Subunit Vaccines, Live Attenuated Virus Vaccines), Age Group (Pediatric, Adult), End User (Hospitals and Clinics, Research Organizations and Academic Institutes, Others), Dosage Form (Nasal Spray, Intramuscular Injection, Intradermal Shot) – Industry Trends and Forecast to 2029.
Flu Vaccines Market Analysis and Size
The main focus of UNICEF's activities for the past 70 years has been immunisation. There is no organisation more suited to provide for children all across the world. As a technical partner of the Indian government's immunisation programme, UNICEF is dedicated to helping the government make sure that no child suffers from illnesses that can be prevented by vaccination.
Data Bridge Market Research analyses that the flu vaccines market which was USD 7.5 billion in 2021, would rocket up to USD 14.83 billion by 2029, and is expected to undergo a CAGR of 8.90% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Flu Vaccines Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Influenza Type (Seasonal, Zoonotic), Manufacturing Technology (Egg-Based, Cell Culture-Based, Recombinant-Based), Vaccine Type (Quadrivalent Influenza Vaccines, Trivalent Influenza Vaccines, Whole Virus Vaccines, Split Virus Vaccines, Subunit Vaccines, Live Attenuated Virus Vaccines), Age Group (Pediatric, Adult), End User (Hospitals and Clinics, Research Organizations and Academic Institutes, Others), Dosage Form (Nasal Spray, Intramuscular Injection, Intradermal Shot)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
AstraZeneca (U.K.), BioDiem (Canada), Novasep (France), Merck KGaA (Germany), Charles River Laboratories (U.K.), uniQure N.V. (Netherlands), Waisman Biomanufacturing (U.S.), Creative-Biogene (U.S.), Aldevron (U.S.), Oxford Biomedica (U.K.), Thermo Fisher Scientific Inc (U.S.), Fujifilm Corporation (Japan), Spark Therapeutics Inc. (U.S.), ABL Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Brammer Bio (U.S.), Pfizer Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Vaccinations against influenza are referred to as "flu injections" or "influenza vaccinations". The influenza virus's fast evolution, a new vaccination is created twice a year. Although this changes from year to year, the most offer modest to strong protection against influenza. There is little evidence among persons over 65. On average, they missed their work days by one and a half days. A child's surroundings may be protected through vaccination.
Global Flu Vaccines Market Dynamics
Drivers
- Surging volume of patients suffering from Flu
The characteristics of circulating viruses, the timing of the season, how well the vaccine protects against illness, and how many people received vaccinations all play a role in determining the severity of flu disease in the United States. Flu has a variety of consequences. CDC estimates that flu has resulted in 9 million – 41 million illnesses, 140,000 – 710,000 hospitalizations and 12,000 – 52,000 deaths annually between 2010 and 2020. This will boost market’s growth.
- Raising awareness of immunization
One of the most effective and economical health interventions in the world, vaccination saves millions of lives every year. Worldwide, vaccinations prevent infectious diseases such as hepatitis, diphtheria, tetanus, pertussis (whooping cough), measles, and polio from killing up to 3 million people each year. Nevertheless, despite the vaccines' demonstrable efficacy and the tens of millions of lives they have saved, an estimated 400 000 people in the Western Pacific Region pass away needlessly each year from diseases that immunizations could have prevented. Up to 800 000 kids are not immunised each year, and more than 3.2 million kids reside in areas with immunisation coverage rates under 80%. This will boost the market growth.
Opportunities
- Government initiatives
According to a recent survey conducted in the 190 districts where Mission Indradhanush has recently been implemented, the percentage of children who have received all recommended vaccinations has grown by 18.5% since pre-Mission Indradhanush estimations. To achieve and maintain India's goal of 90% full immunisation coverage, Mission Indradhanush's lessons are being applied to find all uninvited children nationwide.
Restraints/Challenges
- High cost
On the other hand, the stringent regulations regarding the implementation and timelines along with high cost of vaccine development will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the flu vaccines market.
This flu vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the flu vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Flu Vaccines Market
The global flu vaccines market is expected to rise as a result of the COVID-19 outbreak. As more people become infected with the COVID-19 virus, demand for the flu vaccines rises. The flu vaccine will not protect against COVID-19, but it will lessen sickness, hospitalisation, and mortality. In 2021, it was announced by the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) that 75,000 COVID-19 patients who received the flu vaccine were less likely to develop sepsis, stroke, and deep vein thrombosis. According to the same source, it was discovered in 2021 that the flu vaccine might provide defence against the COVID-19 virus. Patients with COVID-19 who have received an influenza vaccination had a lower likelihood of being admitted to an intensive care unit.
Recent Development
- In February 2021, A legally binding agreement was reached by GlaxoSmithKline plc and Vir Biotechnology, Inc. to broaden their current partnership to encompass the investigation and creation of fresh treatments for influenza and other respiratory viruses.
- In March 2021, At its current location in Toronto, Canada, Sanofi announced that it will invest more than €600 million in a new vaccine manufacturing facility.
- In November 2020, Seqirus announced that it would build a brand-new, top-notch biotech manufacturing plant in Australia to provide influenza vaccinations to that country and the rest of the world.
Global Flu Vaccines Market Scope
The flu vaccines market is segmented on the basis of influenza type, manufacturing technology, vaccine type, age group, dosage form and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Influenza Type
- Seasonal
- Zoonotic
Manufacturing Technology
- Egg-Based
- Cell Culture-Based
- Recombinant-Based
Vaccine Type
- Quadrivalent Influenza Vaccines
- Trivalent Influenza Vaccines
- Whole Virus Vaccines
- Split Virus Vaccines
- Subunit Vaccines
- Live Attenuated Virus Vaccines
Age Group
- Pediatric
- Adult
End User
- Hospitals and Clinics
- Research Organizations and Academic Institutes
- Others
Dosage Form
- Nasal Spray
- Intramuscular Injection
- Intradermal Shot
Flu Vaccines Market Regional Analysis/Insights
The flu vaccines market is analysed and market size insights and trends are provided by country, influenza type, manufacturing technology, vaccine type, age group, dosage form and end user as referenced above.
The countries covered in the flu vaccines market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the flu vaccines market due to the growing number of geriatric population along with adoption of innovative medical technology.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the demand for efficient vaccinations is likely to increase.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Flu Vaccines Market Share Analysis
The flu vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to flu vaccines market.
Some of the major players operating in the flu vaccines market are:
- AstraZeneca (U.K.)
- BioDiem (Canada)
- Novasep (France)
- MerckKGaA (Germany)
- Charles River Laboratories (U.K.)
- uniQure N.V. (Netherlands)
- Waisman Biomanufacturing (U.S.)
- Creative-Biogene (U.S.)
- Aldevron (U.S.)
- Oxford Biomedica (U.K.)
- Thermo Fisher Scientific Inc (U.S.)
- Fujifilm Corporation (Japan)
- Spark Therapeutics Inc. (U.S.)
- ABL Inc. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Brammer Bio (U.S.)
- Pfizer Inc. (U.S.)
SKU-